Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Total revenues	$ 38,406	$ 25,453	$ 73,746	$ 43,485
Cost of product revenue	11,270	4,318	19,791	8,536
Research and development	19,089	12,826	38,590	24,397
Selling, general and administrative	10,656	12,795	26,360	24,193
Total costs and operating expenses	41,015	29,939	84,741	57,126
Income (loss) from operations	(2,609)	(4,486)	(10,995)	(13,641)
Unallocated depreciation and amortization	(1,341)	(716)	(2,556)	(1,375)
Stock-based compensation	3,231	2,844	7,069	5,531
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	36,530	21,585	69,629	35,815
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	1,876	3,868	4,117	7,670
Product revenue
Segment Reporting Information [Line Items]
Total revenues	34,645	14,717	65,335	24,943
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	34,645	14,717	65,335	24,943
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	3,761	10,736	8,411	18,542
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	1,885	6,868	4,294	10,872
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	1,876	3,868	4,117	7,670
Operating segments
Segment Reporting Information [Line Items]
Total revenues	38,406	25,453	73,746	43,485
Cost of product revenue	11,270	4,318	19,791	8,536
Research and development	18,007	12,251	36,475	23,301
Selling, general and administrative	4,556	3,790	8,816	7,209
Total costs and operating expenses	33,833	20,359	65,082	39,046
Income (loss) from operations	4,573	5,094	8,664	4,439
Stock-based compensation	3,231	2,844	7,069	5,531
Operating segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	36,530	21,585	69,629	35,815
Cost of product revenue	11,270	4,318	19,791	8,536
Research and development	6,929	5,057	13,051	11,502
Selling, general and administrative	3,876	3,170	7,416	5,988
Total costs and operating expenses	22,075	12,545	40,258	26,026
Income (loss) from operations	14,455	9,040	29,371	9,789
Stock-based compensation	1,283	1,115	2,770	2,109
Operating segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	1,876	3,868	4,117	7,670
Cost of product revenue	0	0	0	0
Research and development	11,078	7,194	23,424	11,799
Selling, general and administrative	680	620	1,400	1,221
Total costs and operating expenses	11,758	7,814	24,824	13,020
Income (loss) from operations	(9,882)	(3,946)	(20,707)	(5,350)
Stock-based compensation	358	257	768	495
Operating segments | Product revenue
Segment Reporting Information [Line Items]
Total revenues	34,645	14,717	65,335	24,943
Operating segments | Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	3,761	10,736	8,411	18,542
Corporate, non-segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	(5,789)	(8,610)	(16,994)	(16,335)
Unallocated depreciation and amortization	(1,316)	(741)	(2,549)	(1,426)
Income (loss) before income taxes	(2,532)	(4,257)	(10,879)	(13,322)
Stock-based compensation	$ 1,590	$ 1,472	$ 3,531	$ 2,927